Positron emission tomography (PET) measurement of the displaceability of [11C]FLB 457 from extra-striatal dopamine D2 receptors in man

Submission date	Recruitment status No longer recruiting	Prospectively registered		
30/09/2004		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/09/2004	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
01/12/2010	Other			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Paul Grasby

Contact details

c/o Lindsay Green, Assistant Direct MRC Cyclotron Unit PET Neuroscience Hammersmith Hospital Du Cane Road London United Kingdom W12 0HS +44 (0)20 8383 3162 paul.grasby@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0016131985

Study information

Scientific Title

Study objectives

- 1. To measure binding of [11C]FLB 457 after the administration of methylphenidate and placebo in normal volunteers.
- 2. To determine if [11C]FLB 457 is displaceable in extra-striatal regions of the brain.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Not Applicable: Metabolism

Interventions

Double-blind, placebo controlled, randomised study to measure binding of [11C]FLB 457 after the administration of methylphenidate and placebo in normal volunteers.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

methylphenidate

Primary outcome measure

To measure accurately extra-striatal dopamine D2 receptor density in man. If [11C]FLB 457 is displaceable from extrastriatal D2 receptors, it will have great potential value for the measurement of extrastriatal dopamine levels.

Secondary outcome measures

Not provided at time of registration

Overall study start date

02/09/2001

Completion date

03/09/2005

Eligibility

Key inclusion criteria

Volunteers: 16. Males 25-65 yrs, females 45-65 yrs.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

16

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

02/09/2001

Date of final enrolment

03/09/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre c/o Lindsay Green, Assistant Direct London United Kingdom W12 0HS

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

Hammersmith Hospital NHS Trust

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2007		Yes	No